About Celsis
Celsis is a company based in Chicago (United States) founded in 1994 was acquired by BioIVT in July 2013. Celsis has raised $36.8 million across 1 funding round from investors including BioIVT and Harwood Private Equity. Celsis operates in a competitive market with competitors including Evelo Biosciences, PathogenDX, AFYREN, Spore Biotechnologies and Perfectus Biomed, among others.
- Headquarter Chicago, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Celsis
Celsis has successfully raised a total of $36.8M through 1 strategic funding round. The most recent funding activity was a Series B round of $36.8 million completed in September 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celsis
Celsis has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BioIVT and Harwood Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Harwood Private Equity is focused on UK mid-market investments.
|
Locked | Locked | Locked | |
|
Provider of in vitro diagnostic products and assay services
|
Locked | Locked | Locked |
Investor details for Celsis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celsis
Investment portfolio details for Celsis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celsis
Detailed financials for Celsis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celsis Comparisons
Peer comparison for Celsis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celsis
Celsis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, PathogenDX, AFYREN, Spore Biotechnologies and Perfectus Biomed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
|
| Locked | Locked | Locked |
Microbial detection technology is developed for life science industries.
|
|
| Locked | Locked | Locked |
Provides services for research-based approach for microbiological testing
|
Detailed competitors of Celsis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celsis
Complete news archive for Celsis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celsis
Celsis was founded in 1994 and raised its 1st funding round 15 years after it was founded.
Celsis is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Celsis is a funded company, having raised a total of $36.8M across 1 funding round to date.
Celsis was founded in 1994 and is based in Chicago, United States. Operations focus on the biopharmaceutical and consumer products industries, where rapid microbial screening systems are produced for quality control. These systems are utilized in non-sterile and sterile applications to detect the presence or absence of contaminations, supporting compliance and safety standards across manufacturing processes.
Celsis's top competitors include PathogenDX, AFYREN and Perfectus Biomed.
Celsis has 2 investors. Key investors include BioIVT, and Harwood Private Equity.